Avidity Biosciences Announced New Long-term AOC 1001 Data From The Marina-OLE Trial Showing Reversal Of Disease Progression In Myotonic Dystrophy Type 1 Patients Across Multiple Endpoints

-4.12%

Avidity Biosciences

RNA

0.00

These endpoints are the same key endpoints that will be used in the global Phase 3 HARBOR trial for people living with DM1.vidity is accelerating the global Phase 3 HARBOR trial initiation to the second quarter of 2024.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.